161 related articles for article (PubMed ID: 7510192)
1. Prevention of chemotherapy-induced neutropenia using G-CSF with VACOP-B--a case report.
Anglin P; Strauss BA; Brandwein JM
Leuk Lymphoma; 1993 Nov; 11(5-6):469-72. PubMed ID: 7510192
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte colony-stimulating factor (G-CSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy.
Dotti G; Stella CC; Mangoni L; Cottafavi L; Caramatti C; Almici C; Rizzoli V
Haematologica; 1995; 80(2):142-5. PubMed ID: 7543069
[TBL] [Abstract][Full Text] [Related]
3. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte colony stimulating factor (G-CSF) as adjunct therapy in relapsed-resistant high-grade non-Hodgkin's lymphoma.
Zinzani PL; Martelli M; Tura S; Mandelli F
Haematologica; 1993; 78(1):40-3. PubMed ID: 7684011
[TBL] [Abstract][Full Text] [Related]
5. The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease.
Silvestri F; Fanin R; Velisig M; Barillari G; Virgolini L; Zaja F; Russo D; Baccarani M
Tumori; 1994 Dec; 80(6):453-8. PubMed ID: 7534963
[TBL] [Abstract][Full Text] [Related]
6. Effects of rhG-CSF on infection complications and impaired function of neutrophils secondary to chemotherapy for non-Hodgkin's lymphoma. Hokkaido Study Group of Malignant Lymphoma, and rhG-CSF, Japan.
Kuni-Eda Y; Okabe M; Kurosawa M; Maekawa I; Higuchi M; Kawamura M; Morioka M; Suzuki S; Ohmura T; Fujimoto N
Leuk Lymphoma; 1995 Feb; 16(5-6):471-6. PubMed ID: 7540462
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas.
Silvestri F; Velisig M; Fanin R; Virgolini L; Zaja F; Barillari G; Baccarani M
Leuk Lymphoma; 1995 Feb; 16(5-6):465-70. PubMed ID: 7540461
[TBL] [Abstract][Full Text] [Related]
8. P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL).
Bertini M; Freilone R; Vitolo U; Botto B; Pizzuti M; Gavarotti P; Levis A; Orlandi E; Orsucci L; Pini M
Ann Oncol; 1994 Dec; 5(10):895-900. PubMed ID: 7535080
[TBL] [Abstract][Full Text] [Related]
9. A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group.
Santini G; De Souza C; Aversa S; Patti C; Tedeschi L; Candela M; Olivieri A; Chisesi T; Rubagotti A; Centurioni R; Nardi V; Congiu M; Gennaro M; Truini M;
Braz J Med Biol Res; 2004 May; 37(5):719-28. PubMed ID: 15107935
[TBL] [Abstract][Full Text] [Related]
10. Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma.
Niitsu N; Umeda M
Eur J Haematol; 1996 Mar; 56(3):163-7. PubMed ID: 8598236
[TBL] [Abstract][Full Text] [Related]
11. The MACOP-B and VACOP-B combination chemotherapy for young patients with intermediate-grade non-Hodgkin's lymphoma.
Dreiher J; Shpilberg O; Raanani P; Chetrit A; Ben-Bassat I
Leuk Res; 1998 Nov; 22(11):997-1002. PubMed ID: 9783801
[TBL] [Abstract][Full Text] [Related]
12. [A double-blind, cross-over clinical trial of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin's lymphoma].
Oyama A; Ota K; Asano S; Takaku F; Yoshida Y; Uzuka Y; Omine M; Furusawa S; Takatani O; Sawada U
Nihon Gan Chiryo Gakkai Shi; 1990 Oct; 25(10):2533-48. PubMed ID: 1702132
[TBL] [Abstract][Full Text] [Related]
13. Severe neutropenia and relative dose intensity among patients<65 and ≥65 years with non-Hodgkin's lymphoma receiving CHOP-based chemotherapy.
Schwartzberg LS; Saleh M; Whittaker S; Abella E
Support Care Cancer; 2014 Jul; 22(7):1833-41. PubMed ID: 24535242
[TBL] [Abstract][Full Text] [Related]
14. COP-BLAM regimen combined with granulocyte colony-stimulating factor and high-grade non-Hodgkin's lymphoma.
Niitsu N; Umeda M
Eur J Haematol; 1995 Aug; 55(2):88-92. PubMed ID: 7543059
[TBL] [Abstract][Full Text] [Related]
15. High incidence of chemotherapy-induced acral erythema in female patients with non-Hodgkin's lymphoma treated with the VACOP-B regimen.
Ogawa H; Sugiyama H; Tani Y; Soma T; Yamagami T; Tatekawa T; Oji Y; Kubota T; Kimura T; Inoue K; Nakagawa M; Sasaki K; Matsunashi T; Miyake S; Kishimoto T
Leuk Lymphoma; 1998 Mar; 29(1-2):171-7. PubMed ID: 9638986
[TBL] [Abstract][Full Text] [Related]
16. [Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin's lymphoma].
Oyama A; Ota K; Asano S; Takaku F; Miyazaki T; Uzuka Y; Omine M; Furusawa S; Hirashima K; Sanpi K
Nihon Gan Chiryo Gakkai Shi; 1990 Aug; 25(8):1619-34. PubMed ID: 1700040
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial.
Pettengell R; Gurney H; Radford JA; Deakin DP; James R; Wilkinson PM; Kane K; Bentley J; Crowther D
Blood; 1992 Sep; 80(6):1430-6. PubMed ID: 1381626
[TBL] [Abstract][Full Text] [Related]
18. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
[TBL] [Abstract][Full Text] [Related]
19. Transplantation potential of peripheral whole blood primed by VACOP-B chemotherapy plus filgrastim (r-metHuG-CSF) in patients with aggressive non-Hodgkin's lumphoma.
Corato A; Ambrosetti A; Rossi B; Vincenzi C; Lambiase A; Perona G; Pizzolo G; de Wynter E; Nadali G
J Hematother Stem Cell Res; 2000 Oct; 9(5):673-82. PubMed ID: 11091491
[TBL] [Abstract][Full Text] [Related]
20. [VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report].
Ishii K; Yamamoto Y; Shigeki T; Kitayama H; Hayashi K; Hirose A; Ohta T; Mugitani A; Fujino H; Yagi T; Hirai M; Teshima H; Katsurada T; Urase F; Kitajima H
Gan To Kagaku Ryoho; 2005 Jan; 32(1):39-44. PubMed ID: 15675580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
